Advar Pharma Winstrol 50

Advar Pharma Winstrol 50 (Stanozolol 50mg) | NexorinPharma

Advar Pharma Winstrol 50 is an oral anabolic steroid containing 50mg of Stanozolol per tablet. At NexorinPharma, we carry Advar Pharma Winstrol 50 as part of our oral anabolic steroid inventory for customers in markets where Stanozolol is legally available.

Stanozolol is the active compound in Winstrol 50. It is a synthetic anabolic-androgenic steroid derived from Dihydrotestosterone with a documented clinical history spanning several decades. Unlike many anabolic steroids discussed in performance communities, Stanozolol carries a documented history of FDA approval for specific clinical indications, though that approval has since been withdrawn from the US market for most applications.

The 50mg tablet concentration of Advar Pharma Winstrol 50 represents a higher per-tablet dose than the standard pharmaceutical grade Stanozolol tablet formats historically available in clinical settings. This distinction is important context for anyone researching this specific product.

Like all anabolic-androgenic steroids, Advar Pharma Winstrol 50 carries significant health and legal considerations. This page covers what Stanozolol is, how it works, and what health and legal considerations apply. It does not constitute medical advice. It does not recommend or encourage steroid use. It does not provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

Website: nexorinpharma.com Product Name: Advar Pharma Winstrol 50 Manufacturer: Advar Pharma Active Compound: Stanozolol Also Known As: Winstrol, Stromba, Stanozolol Drug Class: Anabolic-androgenic steroid, 17-alpha alkylated oral steroid, DHT derivative Concentration: 50mg per tablet Presentation: Oral tablet Form: Tablet Half-Life: Approximately 9 hours Route of Administration: Oral Anabolic Rating: 320 relative to testosterone baseline of 100 Androgenic Rating: 30 relative to testosterone baseline of 100 Aromatization: None 17-Alpha Alkylated: Yes Liver Toxicity: Significant Legal Status: Schedule III controlled substance in the United States. Prescription required. Legal status varies by country.

About Advar Pharma

Advar Pharma is a non-prescription anabolic steroid manufacturer producing oral and injectable products for markets where such compounds are legally available. The brand carries a presence in international bodybuilding and performance communities and produces its product range with pharmaceutical-style presentation and clear compound labeling.

Like all manufacturers operating outside regulated pharmaceutical channels, Advar Pharma does not carry the manufacturing oversight, regulatory scrutiny, or clinical trial documentation of pharmaceutical grade prescription products. Consequently, quality, purity, and concentration accuracy are less verifiable than with regulated products. Within the non-prescription market, however, Advar Pharma is referenced for product presentation and labeling clarity across international performance communities.

What Is Stanozolol

Stanozolol is a synthetic anabolic-androgenic steroid derived from Dihydrotestosterone. Winthrop Laboratories developed it in 1962 and introduced it to the US market under the brand name Winstrol. From the beginning, it was developed with both clinical and performance applications in mind, distinguishing it from compounds developed exclusively for one purpose.

Structurally, Stanozolol is a modified form of DHT. Two key structural modifications define it. First, a methyl group at the 17-alpha position allows it to survive first-pass liver metabolism when taken orally. Second, a pyrazole ring is fused to the A-ring of the steroid structure at the 3,2-c position. This pyrazole ring modification is the most pharmacologically significant structural feature of Stanozolol, producing its distinct anabolic-to-androgenic ratio and eliminating its susceptibility to aromatization.

Together, these structural modifications produce an oral anabolic steroid with an anabolic rating of 320 and an androgenic rating of 30 relative to a testosterone baseline of 100. Strong anabolic activity combined with low androgenic potency and no estrogenic conversion consequently defines its pharmacological profile.

How Stanozolol Works

Stanozolol is active when taken orally. The 17-alpha alkylation allows it to pass through the liver without complete breakdown, reaching systemic circulation in active form.

Androgen Receptor Binding

Stanozolol binds to androgen receptors throughout the body. Its androgenic activity is significantly lower than testosterone despite its meaningful anabolic rating. As a result, androgen receptor activation in muscle tissue drives its anabolic effects while producing comparatively lower androgenic activity in androgen-sensitive tissues like skin and hair follicles compared to full androgenic compounds.

SHBG Binding

Stanozolol carries a notable ability to bind to sex hormone-binding globulin with high affinity. SHBG binds to testosterone and other androgens in circulation, rendering them biologically inactive. By competing for SHBG binding, Stanozolol reduces the proportion of other androgens bound to SHBG, increasing free androgen availability in circulation. This SHBG binding characteristic is one of the most consistently referenced pharmacological properties of Stanozolol in performance community discussions.

Nitrogen Retention

Stanozolol produces positive nitrogen retention in muscle tissue. The body retains more nitrogen than it excretes. Consequently, this supports an anabolic environment that favors muscle repair and maintenance. This mechanism contributes to the lean mass preservation observations consistently discussed in performance communities about Stanozolol use.

Protein Synthesis

Stanozolol accelerates protein synthesis in skeletal muscle tissue. Faster protein synthesis supports muscle repair and growth following training. This mechanism is directly tied to its androgen receptor activity and contributes to its anabolic profile in both clinical and performance contexts.

No Aromatization

Stanozolol does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative with a pyrazole ring modification, it is not a substrate for aromatase. Consequently, estrogen-related side effects including water retention and gynecomastia are not part of its direct pharmacological profile. This characteristic distinguishes it from testosterone and many other anabolic steroids where estrogenic conversion is a primary side effect consideration.

No Progestogenic Activity

Stanozolol does not show clinically significant affinity for progesterone receptors. This distinguishes it from compounds like Trenbolone and Nandrolone where progestogenic activity is a primary side effect consideration. As a result, Stanozolol carries a cleaner overall hormonal side effect profile compared to progestogenic anabolic steroids.

Clinical Background

Stanozolol carries a documented clinical history that provides relevant context for its pharmacological profile.

Hereditary Angioedema

The most clinically significant approved application of Stanozolol is the treatment and prevention of hereditary angioedema, a condition characterized by recurrent episodes of severe swelling in the face, extremities, genitals, bowel wall, and airway. The FDA approved Stanozolol for this indication and clinical research documents meaningful reductions in the frequency and severity of hereditary angioedema attacks with Stanozolol treatment. This clinical application reflects a distinct pharmacological mechanism through anabolic steroid-mediated upregulation of C1 inhibitor complement protein production.

Anemia Treatment

Stanozolol was used clinically for the treatment of certain anemias, particularly aplastic anemia, through its stimulatory effects on erythropoiesis. This application reflects its documented effects on red blood cell production through androgen receptor-mediated mechanisms. The anemia treatment application has largely been replaced by more targeted therapies in current clinical practice.

Wasting Conditions

Stanozolol was investigated and used clinically for muscle wasting conditions and general debilitation in several markets. Its anabolic properties and relatively low androgenic profile compared to testosterone made it a relevant clinical compound for these applications. This clinical use history provides additional context for understanding its pharmacological profile beyond performance community discussions.

About the 50mg Concentration

The 50mg per tablet concentration of Advar Pharma Winstrol 50 significantly exceeds the standard pharmaceutical grade Stanozolol tablet formats historically available in clinical settings. Understanding this distinction is important context for anyone researching this specific product.

Comparison With Standard Clinical Formats

Pharmaceutical grade Winstrol was historically available at 2mg tablet formats for oral clinical use. The 50mg concentration of Advar Pharma Winstrol 50 consequently represents 25 times the historical standard pharmaceutical tablet format. This significantly higher concentration per tablet carries considerably greater liver toxicity and other dose-dependent side effect considerations compared to standard clinical dose formats.

Non-Prescription Market Context

Higher concentration Stanozolol tablet formats of 10mg, 25mg, and 50mg are produced by various manufacturers in non-prescription markets. Advar Pharma Winstrol 50 sits at the higher end of these non-prescription concentration formats. As a result, the side effect considerations associated with higher Stanozolol concentrations, particularly regarding liver toxicity and lipid effects, are particularly relevant to this specific product.

Liver Toxicity at Higher Concentrations

Stanozolol’s hepatotoxicity profile from 17-alpha alkylation is documented in clinical research at standard doses. The 50mg concentration of Advar Pharma Winstrol 50 represents a substantially higher per-tablet concentration than standard clinical formats. Consequently, liver stress considerations are significantly more pronounced at this concentration than the clinical research base at standard doses fully reflects.

Advar Pharma Winstrol 50 Versus Other Oral Anabolic Steroids

Versus Oxandrolone (Anavar)

Oxandrolone is another DHT-derived non-aromatizing oral anabolic steroid. Both Stanozolol and Oxandrolone are non-aromatizing compounds that do not convert to estrogen. However, Oxandrolone carries significantly milder liver toxicity than Stanozolol and a lower androgenic rating of 24 compared to Stanozolol’s 30. Furthermore, Oxandrolone retains active FDA approval while Stanozolol’s US market approval has been largely withdrawn. As a result, Oxandrolone represents a milder hepatotoxicity and androgenic profile than Stanozolol across multiple parameters.

Versus Methandrostenolone (Dianabol)

Methandrostenolone aromatizes significantly to estrogen and carries pronounced estrogenic side effects. Stanozolol, on the other hand, does not aromatize and carries no estrogenic conversion. Both are 17-alpha alkylated oral steroids with significant liver toxicity. However, Stanozolol’s absence of estrogenic side effects and its SHBG binding characteristics produce a fundamentally different pharmacological profile from Methandrostenolone’s aromatizing and estrogenic profile.

Versus Oxymetholone (Anadrol)

Oxymetholone is one of the most potent oral anabolic steroids available with the most significant liver toxicity profile among commonly discussed oral anabolic steroids. Compared to Oxymetholone, Stanozolol carries a more moderate potency profile with significant but less extreme liver toxicity. In addition, Stanozolol does not produce the pronounced estrogenic effects associated with Oxymetholone despite not directly aromatizing.

Versus Turinabol

Turinabol is a non-aromatizing oral anabolic steroid with a moderate anabolic profile and a cleaner side effect profile than Stanozolol in terms of liver toxicity and lipid effects. Both Turinabol and Stanozolol are non-aromatizing. However, Stanozolol’s higher anabolic rating of 320 compared to Turinabol’s more moderate profile, combined with its SHBG binding characteristic, distinguishes it pharmacologically. Furthermore, Stanozolol’s more significant liver toxicity and adverse lipid effects represent a more pronounced side effect profile than Turinabol’s.

Versus Methenolone Acetate (Oral Primobolan)

Methenolone Acetate is an oral non-aromatizing anabolic steroid with notably milder liver toxicity than Stanozolol due to its non-17-alpha alkylated structure. Stanozolol carries significantly higher anabolic activity than Methenolone Acetate. However, the absence of 17-alpha alkylation in Methenolone Acetate produces a fundamentally more favorable liver stress profile. As a result, these two non-aromatizing oral compounds carry distinct trade-offs between anabolic potency and hepatotoxicity risk.

Side Effects and Health Risks

Advar Pharma Winstrol 50 carries a significant side effect profile. The higher 50mg concentration per tablet makes these side effect considerations more pronounced than with lower-concentration Stanozolol formats.

Liver Toxicity

Liver toxicity is the most serious health concern associated with Stanozolol use. As a 17-alpha alkylated oral steroid, the alkylation that allows oral bioavailability places significant stress on liver tissue. Clinical research and case reports document elevated liver enzymes, cholestasis, peliosis hepatis, and in cases of prolonged or high-dose use, more serious hepatic complications including liver tumors. The 50mg concentration of Advar Pharma Winstrol 50 makes liver monitoring through regular blood work particularly important and urgent compared to lower-concentration Stanozolol formats.

Cardiovascular Effects

Stanozolol produces some of the most adverse lipid profile changes of any oral anabolic steroid. HDL cholesterol drops dramatically while LDL cholesterol increases substantially. These lipid changes carry serious long-term cardiovascular health implications. Furthermore, the severity of Stanozolol’s lipid dysregulation is consistently documented as more pronounced than most other oral anabolic steroids in clinical and observational research. Regular lipid monitoring is therefore essential for anyone using this compound.

Androgenic Effects

Despite its relatively low androgenic rating of 30, Stanozolol still produces androgenic side effects in susceptible individuals. These include accelerated hair loss in genetically predisposed individuals and acne on the face and back. In women, virilization effects including voice deepening, clitoral enlargement, and changes in body hair distribution are serious considerations even at lower doses given Stanozolol’s meaningful anabolic potency.

Joint and Connective Tissue Effects

Stanozolol is consistently associated with joint pain and connective tissue discomfort in performance community discussions and observational reports. The proposed mechanism involves Stanozolol’s interaction with collagen synthesis pathways and its anti-estrogenic properties, as estrogen plays a role in joint lubrication and connective tissue health. This side effect is among the most consistently reported in Stanozolol discussions and is relevant to anyone using this compound.

Hormonal Suppression

Stanozolol suppresses the hypothalamic-pituitary-gonadal axis and the body’s natural testosterone production. Post-use hormonal disruption can persist for months. In some cases, it results in hypogonadism requiring medical treatment. Hormonal monitoring and post-use recovery support are consequently relevant health considerations for anyone using this compound.

Psychological Effects

Anabolic steroid use carries documented associations with mood changes and irritability. These considerations apply to Stanozolol use. They are generally less pronounced than with higher androgenic compounds but remain relevant health considerations at the 50mg concentration of Advar Pharma Winstrol 50.

Legal and Regulatory Status

Stanozolol carries Schedule III controlled substance status in the United States under the Controlled Substances Act. Its FDA approval for hereditary angioedema has been commercially discontinued in the US market, though the compound retains Schedule III scheduling. Possession without a valid prescription is a federal offense.

In the United Kingdom, Stanozolol falls under Class C of the Misuse of Drugs Act. Supply is illegal.

The World Anti-Doping Agency bans Stanozolol alongside all major athletic governing bodies. It has been at the center of several high-profile doping cases in competitive sports history, most notably the Ben Johnson case at the 1988 Seoul Olympics. It consequently appears on prohibited substance lists across Olympic sports, professional athletics, and competitive bodybuilding organizations that conduct testing.

You are responsible for confirming the legal status of Stanozolol in your specific jurisdiction before purchasing from NexorinPharma.

Frequently Asked Questions

Is Advar Pharma Winstrol 50 Available at NexorinPharma

Yes. NexorinPharma carries Advar Pharma Winstrol 50 for customers in markets where Stanozolol is legally available. Visit nexorinpharma.com to check current availability and pricing.

What Is the Half-Life of Stanozolol

Stanozolol produces a half-life of approximately 9 hours for the oral tablet form. As a result, regular daily administration is required to maintain stable plasma concentrations throughout the day.

Does Stanozolol Aromatize

No. Stanozolol does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative with a pyrazole ring modification, it is not a substrate for aromatase. Consequently, estrogen-related side effects are not part of its direct pharmacological profile.

What Makes Stanozolol Different From Other DHT Derivatives

Stanozolol’s pyrazole ring fusion at the A-ring of the steroid structure is its most pharmacologically distinctive structural feature. This modification is unique among commonly discussed anabolic steroids and produces its distinct anabolic-to-androgenic ratio, its complete resistance to aromatization, and its notable SHBG binding affinity. Furthermore, its documented clinical application in hereditary angioedema through C1 inhibitor upregulation represents a pharmacological mechanism distinct from most other anabolic steroids.

What Are the Most Serious Health Risks

Liver toxicity from 17-alpha alkylation is the most serious health concern with Stanozolol, particularly at the higher 50mg concentration of this product. In addition, severe adverse lipid profile changes producing significant cardiovascular risk, joint and connective tissue effects, hormonal suppression, and androgenic effects complete the primary risk profile. Medical supervision and regular blood work monitoring including liver enzymes and lipid panels are therefore essential for anyone using this compound.

Is Advar Pharma Winstrol 50 Legal to Purchase

Stanozolol carries Schedule III controlled substance status in the United States and requires a valid prescription. Legal status varies by jurisdiction. You are responsible for confirming the legal status in your jurisdiction before purchasing from NexorinPharma.

What to Consider Before Purchasing Advar Pharma Winstrol 50

Stanozolol has a documented clinical history and a well-established presence in bodybuilding and performance community discussions spanning several decades. Its clinical application in hereditary angioedema, documented anabolic properties, non-aromatizing profile, and notable SHBG binding characteristics contribute to its consistent discussion across international performance communities.

The 50mg concentration of Advar Pharma Winstrol 50 significantly exceeds standard clinical tablet formats historically available in pharmaceutical grade presentations. As a result, the liver toxicity and lipid dysregulation considerations associated with Stanozolol are considerably more pronounced with this specific high-concentration product than at standard lower-dose clinical formats. The clinical research base for Stanozolol at standard doses provides a relevant pharmacological framework but does not fully represent the risk profile at the 50mg concentration outside of clinical supervision.

The Advar Pharma non-prescription format does not carry the manufacturing oversight of pharmaceutical grade products. Furthermore, the significant liver toxicity and cardiovascular risk profile of Stanozolol make quality verification and regular medical monitoring particularly important for anyone using this compound.

Stanozolol carries documented liver, cardiovascular, androgenic, joint, hormonal, and psychological health risks. These risks require medical supervision to manage responsibly. Regular blood work monitoring including liver enzymes, lipid panels, and hormone levels is therefore essential for anyone using this compound.

For customers in markets where Stanozolol is legally available, visit nexorinpharma.com to check current Advar Pharma Winstrol 50 availability, pricing, and stock levels.